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ABSTRACT 
 
An Investigation into the Use of Biokinetic Models When Assessing Intakes of 
Plutonium.  (August 2008) 
Brian Andrew Hrycushko, B.S.; B.S., Texas A&M University 
Chair of Advisory Committee:  Dr. John W. Poston Sr. 
 
The goal of internal dosimetry is to assess the dose to an individual from an 
intake of a radionuclide.  This usually encompasses assessing the intake amount based 
on some form of bioassay measurement used with a biokinetic model.  There are many 
published biokinetic models that describe the transfer of radionuclides throughout the 
body.  It would be beneficial at times if one could interchange certain biokinetic models 
with another to assess an intake based on bioassay data to save time and make 
calculations simpler.  This research compared the daily excretion rates by interchanging 
widely used biokinetic models in different combinations.  These model combinations 
were then used to assess an unknown intake of a case study.   
It was shown that the ICRP-30 and ICRP-66 respiratory tract models can only be 
interchanged at specific times post intake to give similar excretion results from an 
inhalation intake.  It is feasible to interchange the ICRP-67 plutonium systemic model or 
the newer Luciani and Polig plutonium systemic model to assess an intake based on 
fecal bioassay data, but not urine bioassay data for ingestion intakes.  It is not feasible to 
interchange the systemic models when assessing intakes from a wound or injection. 
iv 
 
Using different combinations of biokinetic models predicted intakes within 30% 
for a case study which included a relatively long inhalation chronic intake followed by a 
much shorter chronic inhalation intake.  It was shown that the predicted initial chronic 
intake for each combination of models gave fecal excretion values which deviated the 
most from the worker’s fecal bioassay data.  This could mean that the biokinetic models 
yield inaccurate excretion rates for long chronic intakes. 
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NOMENCLATURE 
 
Bq Becquerel 
d Day 
g Gram 
Gy Gray 
kg Kilogram 
MeV Megaelectron volt 
mSv Millisievert 
Pu Plutonium 
s Seconds 
Sv Sievert 
μm Micrometer 
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CHAPTER I 
INTRODUCTION 
In order to interpret the measurement of activity in excreta it is important to have 
knowledge of the behavior of radioactive materials within the human body.  The 
International Commission on Radiological Protection (ICRP) has developed several 
biokinetic models over the years to describe the transfer of activity throughout the body 
and through routes of excretion.  Some of the models most often used are described in 
ICRP Publications 23 (ICRP 1975), 30 (ICRP 1979), 56 (ICRP 1989), 66 (ICRP 1994), 
67 (ICRP 1993), and 78 (ICRP 1997).  These models are based on linear, first-order 
kinetics with parameters that can be modified so that radionuclide flow throughout the 
body can be represented.  Biokinetic models have been used for dose calculations, 
setting dose limits, and for assessing intakes of radiation based on bioassay 
measurements.  Fig. 1 shows the general form of a biokinetic model of the human body 
(ICRP 1997).  Arrows indicate radionuclide transfer, and boxes indicate specific 
compartments within the body where radionuclide uptake occurs.1Published ICRP 
models describe the respiratory tract, gastrointestinal tract, and systemic systems in more 
detail. 
                                                 
This thesis follows the style of Health Physics. 
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Fig. 1:  General compartmentalized biokinetic model of the human body   
(Adapted from ICRP 1997) 
 
 
It is desired to use bioassay measurements with biokinetic models when 
assessing intakes of radionuclides.  The bioassay measurements used to assess intakes of 
radionuclides can include: in vivo measurements, excretion measurements, air 
monitoring measurements, etc.  The order of preference of assay type, in terms of ease of 
measurements and importance of interpretations is body activity analysis, excretion 
analysis, followed by personal air sampling (ICRP 1997).  Body activity analysis in vivo 
can be used to directly assess the amount of activity in the body, but may only be useful 
for radionuclides that emit x or γ radiation.  Excreta measurements can be used to assess 
intakes, but there is error due to large differences in the rates at which radionuclides 
traverse the body and fluctuations in the amount of an individual’s daily excretion.  The 
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interpretation of air samples may be misleading as the location of the air monitors can 
affect measurements by a factor of about ten (ICRP 1997).  Many bioassay programs 
rely on the analysis of excretion samples as part of their internal exposure control 
program due to lower cost and ease of collection.  It would be beneficial to be able to use 
the excretion measurements with simple biokinetic models to assess correct radionuclide 
intakes with little error.  This would ultimately cut both time and costs of other more 
accurate, but unreasonable intake assessment methods; however, it can often be 
computationally arduous using more complicated models to assess intakes.  
Interchanging models or subsystems of models may speed up the assessment process 
while still providing valid results. 
Urinary excretion is removal of material from the body in urine through the 
bladder.  Fecal excretion is the removal of material that either passes unabsorbed 
through the gastrointestinal tract (GI-tract) or is comprised of systemic material that is 
removed through the GI-tract.  For some radionuclides, including plutonium, routes of 
excretion are given explicitly in biokinetic models (ICRP 1993, Luciani and Polig 2000), 
while other models split excreted activity between urine and feces depending on a 
constant ratio (ICRP 1989).  It can be a difficult task to match the excretion predictions 
from models that split total excretion to actual bioassay measurements, especially for 
chronic intakes over long periods of time or cases where radionuclide intake amounts 
fluctuate over time.   
Plutonium intakes present a problem because it is difficult to measure and 
interpret bioassay data.  Monitoring programs usually collect urine samples due to the 
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ease of collection and esthetic reasons (Cember 1996); however, fecal analysis is 
preferred for such radionuclides such as plutonium with a clearance class of Y (ICRP 
1979) or S (ICRP 1994).  This is because the levels of this class of material in excretion 
can be several orders of magnitude higher in feces than in urine days after a single 
inhalation intake (Khokhryakov et al. 2004).  Urine bioassay data may be more feasible 
for other intake modes, such as wounds or injections, where urine activity levels are the 
same as that of fecal activity levels. 
OBJECTIVES 
The objective of this research is to compare excretion predictions from 
interchanging current and past biokinetic models and use these models to assess an 
unknown intake of plutonium using excretion data.  This is important because plutonium 
is one of the most widely seen elements in occupational exposures.  The goal in 
assessing an unknown intake is to distinguish the correct mode of intake, the amount of 
radionuclide intake, and the time frame of the intake. This will be accomplished by 
developing popular published biokinetic models using the computer program Simulink 
to represent radionuclide transfer through the body and analyze excretion data.  Specific 
goals include: 
 Investigate differences in predicted daily excretion for an acute inhalation intake 
of 239Pu when interchanging the ICRP Publication 30 (ICRP-30) respiratory tract 
model and the ICRP Publication 66 (ICRP-66) respiratory tract models with the 
ICRP Publication 67 (ICRP-67) and the Luciani and Polig plutonium systemic 
models.  This investigation will consider the possibility of interchanging the 
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respiratory models when assessing an intake from excretion data due to the 
difficulty in implementing the ICRP-66 respiratory tract model and all its detail.  
Interchanging the ICRP-30 respiratory tract model for the ICRP-66 respiratory 
tract model could speed up intake assessment and still provide valid results. 
 Investigate differences in plutonium excretion for acute wound/injection and 
ingestion intakes of 239Pu using the ICRP-67 systemic model and a more recent 
plutonium systemic model by Luciani and Polig (Luciani and Polig 2000).  This 
is done because the Luciani and Polig systemic model has been known to give 
better agreement with measured bioassay excretion and higher estimates of 
intake compared with current ICRP models.  This research will investigate the 
possibility of interchanging the biokinetic models when assessing intakes from 
excretion data. 
 Use the biokinetic models in a practical application to assess the intake for a case 
study where there was an unknown intake of 239Pu by a worker.  This is done to 
compare intake assessments and dose calculations based on excretion 
measurements for 239Pu using different combinations of interchanging the 
biokinetic models. 
CASE STUDY OF UNKNOWN INTAKE 
 The biokinetic models will be used to assess the intake for a case study.  A 
worker received a leg laceration during mixed waste processing operations.  Direct 
survey of the workers clothing indicated the presence of contamination, but no 
contamination was found at the wound site.  Twenty-four-hour urinary excretion data 
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were collected periodically and 239Pu content was determined.  However, initial 
measurements suggested a different mode of intake than that from a wound.  Single-
event fecal samples and twenty-four-hour urine samples were then taken periodically 
over a course of several months.  After the laceration, the worker was placed on work 
restriction in areas that did not include elevated radioactivity levels to prevent additional 
intakes.  This worker had been employed at the waste processing site for about 22 
months prior to the laceration event, but did not work in any radiological areas for a 
period of over two months in the middle of employment.  Area monitoring showed 
relatively constant low levels of airborne activity and did not indicate elevated levels of 
activity.  About two months after the worker was placed on restriction, air monitors 
showed a brief five-day spike in airborne activity in non-radioactive work areas that 
could indicate a second intake.  There were a total of seven fecal measurements with six 
positive for 239Pu.  There were a total of seven urinary measurements with only one 
positive for 239Pu.  The one positive urine sample was at such a low level that only fecal 
measurements are used with the biokinetic models in this study.  The combinations of 
biokinetic models will be used to assess the mode of radionuclide intake, the amount of 
radionuclide intake, and the time frame of the radionuclide intake. 
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CHAPTER II 
THEORY 
ICRP PUBLICATION 30 RESPIRATORY TRACT MODEL  
ICRP Publication 2 (ICRP 1959) served as an adequate criterion for the 
controlling of internal radiation exposure, but the maximum permissible concentration in 
air (MPC) and the maximum permissible body burden (MPBB) were often misused or 
misunderstood.  The ICRP-30 respiratory model was an improvement from the ICRP 
Publication 2 respiratory model.  New information on the relationship between ionizing 
radiation and risks to biological effects in the body was the basis for establishing limits 
for exposure to ionizing radiation (ICRP 1979).  The ICRP-30 respiratory model is based 
on a design proposed by the Task Group on Lung Dynamics for Committee II (Task 
Group 2) of the International Radiological Protection Commission.  The Task Group 2 
design determines deposition in and clearance from the human respiratory tract in order 
to calculate dose to the lung and create standard exposure limits.  The committee 
compartmentalized the lung to differentiate deposition and clearance mechanisms (ICRP 
1979).  The compartmentalization depended on lung anatomy, particle deposition 
characteristics, and particle clearance characteristics. 
The ICRP-30 respiratory model is separated in to three regions: the nasal passage 
or the naso-pharyngeal region (N-P), the trachea and bronchial region (T-B), and the 
pulmonary parenchyma region (P).  The N-P region is the upper region of the lung 
starting at the anterior nares and continues down to the larynx.  The T-B region consists 
of the trachea and bronchial tree down through the terminal bronchioles.  This region, 
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together with the N-P region, contains the entire epithelial area of the respiratory tract 
that is ciliated and covered with mucus coming from columnar epithelial cells and 
secretory glands.  The P, together with the T-B region, is the lower respiratory tract.  The 
P region consists of the respiratory bronchioles, the alveolar ducts, and the alveoli. The 
surface of the P region is made up of epithelial cells that are not ciliated.   
Deposition is assumed to depend on the aerodynamic properties of the aerosol in 
question and is determined by the activity median aerodynamic diameter (AMAD).  The 
AMAD is the diameter of a unit sphere that has the same settling velocity as the particle 
(ICRP 1979).  The ICRP-30 respiratory model is meant to be used for particles ranging 
from 0.2 μm to 10 μm AMAD.  The parameters DN-P, DT-B, and DP represent the fraction 
of inhaled material deposited in each region of the lung.  These fractions are given on 
page 25 in ICRP-30 for different AMAD sizes (ICRP 1979).  If the size of inhaled 
particles is unknown, a 1μm AMAD standard sized particle is used where: DN-P is 0.3, 
DT-B is 0.08, and DP is 0.25. 
Particle clearance has been investigated in many studies involving animals and 
humans.  When particles are deposited in the lungs they undergo clearance mainly by 
endocytosis or ciliary movement of mucus.  Endocytosis clearance depends on the 
number, size, shape, and surface reactivity of the particles while clearance by ciliary 
movement seems to be relatively constant.  Each of the three regions of the lung is 
separated into more compartments based on different modes of particles clearance.  The 
ICRP-30 respiratory model considered all published quantitative clearance information 
at the time to assess particle clearance rates.  Three classifications of clearance rate 
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describe removal from the lung: class D materials have clearance half times of less than 
ten days, class W materials have clearance half times from ten to one hundred days, and 
class Y materials have half times greater than one hundred days.  Clearance rates from 
compartment to compartment are defined based on the class of particle.  The activity q 
(Bq) in compartment i at time t (days) after intake is calculated using eqn (1) 
(Khokhryakov et al. 2005). 
 
(1) 
i
n
ij
j
jiR
n
ij
j
jijii
i qqFDtI
dt
tdq
)()(
)(
1
,
1
, 




   
 
where I (t) is the radionuclide intake rate (Bq/day) at time t by inhalation, Di is the 
fraction of the inhaled activity deposited in compartment i, λj,i is the transfer coefficient 
from compartment j to compartment i, λi,j is the transfer coefficient from compartment i 
to compartment j, λR is the radioactive decay constant, and n is the number of 
compartments used in the model.  This equation describes radionuclide flow through the 
respiratory tract through linear, first-order kinetics.  Di is zero for the lymph node 
compartments.  Fig. 2 shows the compartmentalized ICRP-30 respiratory model.  
Arrows define a clearance pathway for radionuclide flow.  Compartments a, c, and e 
represent absorption processes into the systemic circulation.  Compartments b, d, f, and g 
represent particle transport processes to the GI-tract (ICRP 1979).  Compartment h 
represents the slow removal from the pulmonary region to the lymphatic system.  
Material sent to compartment i is transferred to the blood, while material sent to 
compartment j is permanently retained.  The ICRP-30 respiratory model was mainly 
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used in combination with the other ICRP-30 dosimetry models (gastrointestinal tract, 
bone model, systemic model) to establish dose limits and calculate doses to the body or 
organs from known intakes.  It is not used to assess intakes using bioassay measurements 
as there are no specific excretion pathways (Task Group 1966, ICRP 1979). 
 
 
Fig. 2: ICRP Publication 30 respiratory tract model  
(Adapted from ICRP 1979) 
 
 
ICRP PUBLICATION 66 RESPIRATORY TRACT MODEL  
A task group was created to review the respiratory model presented in ICRP-30 
and make revisions based on research since the 1960’s.  This was done in part because 
many studies involving animals resulted in radioactive material being cleared from the 
respiratory tract at different rates than those given by the ICRP-30 model.  The D, W, 
and Y classifications were revised.  The research used to derive the model entailed 
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greater knowledge of the anatomy and physiology of the respiratory tract, the deposition 
and clearance of particles, and the biological effects of radioactive particles.  The ICRP-
30 respiratory model is used to calculate dose by averaging over the entire mass of the 
lung while the ICRP-66 respiratory model takes into account differences in radiation 
sensitivity among the different tissues of the lung and allows the calculation of dose to 
these specific tissues.  This respiratory model is much more complex than that of the 
ICRP-30 respiratory model as more detail is taken into consideration including: age, 
race, sex, breathing characteristics and habits, health detriment of the lungs, and target 
tissues with different sensitivities to radiation (ICRP 1994).  The model of the ICRP-66 
respiratory tract considers the morphometry of the respiratory tract, the respiratory 
physiology, the radiation biology, deposition, clearance, and dosimetry. 
The morphometry of the respiratory tract describes structure and dimensions 
useful in calculating doses.  The respiratory tract is represented as four separate 
anatomical regions: the extra thoracic region (ET), the bronchial region (BB), the 
bronchiolar region (bb), and the alveolar-interstitial region (AI).  Separation of the 
regions is based on anatomical and physiological characteristics along with 
radiobiological response (ICRP 1994).  The ET region is composed of the ET1 (anterior 
nose) and the ET2 (posterior nasal passages, larynx, pharynx, and mouth).  This is the N-
P region of the ICRP-30 respiratory model.  The BB region is composed of the trachea 
and bronchi while the bb region is made up of the bronchioles and terminal bronchioles.  
The BB and bb regions together are the T-B region of the ICRP-30 respiratory tract 
model.  The AI region, which is composed of the respiratory bronchioles, alveolar ducts, 
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and the interstitial connective tissue, is the P region of the ICRP-30 respiratory tract 
model.  Each region contains lymphatic tissue with the ET regions initially clearing to 
the extra-thoracic lymph nodes (LNET) and the BB, bb, and AI regions clearing to the 
thoracic lymph nodes (LNTH).  Average values of cell depths in each region of the lung 
are interpreted from limited information and can be found in ICRP-66 (ICRP 1994).  The 
main advantage of the use of the ICRP-66 respiratory tract model is the ability to tailor 
parameters specifically to individuals. 
A deposition model was created to determine the fraction of inhaled material that gets 
deposited to each region of the respiratory tract (Bair 1995).  ICRP-66 tabulates 
deposition fractions for several sized particles.  Each region of the respiratory tract acts 
as a filter with a filtering efficiency and deposition depending on: 
1. the activity mean thermodynamic diameter (AMTD), which determines 
deposition by thermodynamic processes 
2. the AMAD, which determines deposition by impaction and settling. 
The rate at which material clears each compartment depends on the particle transport 
processes that move material to the GI-tract and lymph nodes and the absorption 
processes moving material to the blood.  The bronchial and bronchiolar regions have 
varying phases of clearance.  To account for the varying phases, these regions were each 
divided in to three compartments: normal phase clearance, slow phase clearance, and a 
separate compartment where activity is transferred to the lymph nodes over time 
(sequestered compartment) (Bair 1995).  There are also three separate phases of 
clearance seen in the alveolar region and it, too, is divided into three compartments.  The 
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absorption process entails both dissolution and uptake.  Dissolution is when particles 
separate to materials that can be absorbed by the blood and uptake is when the material 
dissolved from particles gets absorbed to the blood.  To estimate a time-dependent 
transfer rate, a fraction (fr) dissolves fast (at a rate sr), and a fraction (1-fr) dissolves 
slower (at a rate ss).  To estimate a time-dependent transfer rate which does not have to 
decrease with time, deposited material simultaneously dissolves to blood (at a rate sp) 
and to a transformed state (at a rate spt), where is dissolves to blood (at a rate st).  Uptake 
to blood can be slower due to material binding in the respiratory tract.  Fig. 3 shows the 
compartmental model for the ICRP-66 respiratory tract.  Compartments 1-3 and 14-16 
are the AI1, AI2, and AI3 compartments, respectively.  Compartments 4-6 and 17-19 are 
the bb1, bb2, and bbseq compartments, respectively.  Compartments 7-9 and 20-22 are the 
BB1, BB2, and BBseq compartments, respectively.  Compartments 10 and 23 are LNTH 
compartments.  Compartments 11, 12, 24, and 25 are the ET2 compartments, and 
compartments 13 and 26 are the LNET compartments.  The differential equations 
describing the flow of radionuclides from compartment to compartment are described by 
eqn (1) (Khokhryakov et al. 2005). 
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Fig. 3: Compartmentalized model of the ICRP Publication 66 respiratory tract   
(Adapted from ICRP 1994) 
 
 
ICRP PUBLICATION 30 GASTROINTESTINAL TRACT MODEL 
It is difficult to model the GI-tract because physiological parameters vary from 
person to person. Physiological parameters also vary within an individual depending on 
eating habits and the health of the individual (Skrable et al. 1975). The dosimetric model 
of the ICRP-30 GI-tract is based on the model developed by Eve (Eve 1966).  The ICRP-
30 GI-tract model is made up of four compartments: the stomach, the small intestine 
(SI), the upper large intestine (ULI), and the lower large intestine (LLI).  This model 
treats the GI-tract as a tube through which food will constantly flow until it is excreted at 
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the end (ICRP 1979).  Although absorption of some of the gut contents takes place in the 
SI, ULI, and LLI, it is assumed that radioactive material can only be absorbed to the 
blood and to the rest of the body through the SI compartment.  The fraction of activity 
transferred to the blood is controlled by the F1 value designated to each element and 
implies that the amount of activity reaching the ULI and LLI compartments depends on 
F1 (Dolphin and Eve 1966).  The transfer rates from compartment to compartment and 
the F1 values for different radionuclides can be found in ICRP-30 (ICRP 1979).  These 
values are based on human studies (Eve 1966).  Eqn (2) shows the form of the 
differential equations used to describe the transfer of activity through the GI-tract. )(tI  
is the rate of ingestion of activity of the radionuclide at time t.  This can come from the 
respiratory tract in the case of an inhalation, from an intake occurring by ingestion, or 
from the blood in the case of a wound or injection. 
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Each compartment of the GI-tract is made up of the contents and the wall.  The 
contents are considered the source of the radiation and the walls are considered the target 
of the radiation (ICRP 1979).  Epithelium cells interfering with the contents of GI-tract 
organs are not of importance because they are discarded and damage received by these 
cells is not retained in the sensitive tissue (Eve 1966).  The sensitive cells of the 
epithelium are located on the mucosal surface of the GI tract and are formed deep in the 
16 
 
crypts of the mucosa.  These cells are then pushed up to the contents after a few days 
(ICRP 1979).  The distance between the contents and the sensitive cells causes for the 
use of absorbed fractions that are different depending on radiation penetrability.  This is 
because not all of the energy of the particle is absorbed in the target.  Fig. 4 shows the 
compartmental ICRP-30 GI-tract model. 
 
 
Fig. 4:  Compartmentalized model of the ICRP Publication 30 GI-tract model 
(Adapted from ICRP 1979) 
 
 
ICRP PUBLICATION 67 PLUTONIUM SYSTEMIC MODEL  
For some radionuclides, as is the case for plutonium, there are specific systemic 
biokinetic models used to describe activity transfer.  The old method for determining an 
intake of plutonium given in ICRP Publication 56 (ICRP 1989) was modified based on 
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new information of greater retention in soft tissues (ICRP 1997).  Also, the previous 
models of plutonium did not include the specific excretion pathways for plutonium 
leaving the body.  The ICRP-67 systemic model of plutonium considers the uptake, 
retention, and excretion of activity in greater detail than past systemic models.  This 
model is based on the age-specific biokinetic model for americium (Leggett 1992), with 
the exception that there are two liver compartments for plutonium.  Transfer rates are 
based on in vivo, excretion, and autopsy measurements (ICRP 1993).  Activity is 
transferred to the blood compartment in the systemic model from the respiratory tract 
and the GI-tract.  The ST0 compartment is considered soft tissue comprised of extra-
cellular fluids.  It exchanges activity with the blood in a short period of time (hours or 
days).  Compartments ST1 and ST2 are used to represent large soft tissue (muscle, skin, 
etc.) with a longer period of exchange with the blood (years).  The activity transferred to 
the skeleton is divided among the cortical and trabecular bone.  Each of these is 
subdivided further into volume, surface, and marrow compartments.  Radionuclides 
initially get deposited on the bone surfaces, transferring to the bone marrow by 
resorption and to the bone volume during bone formation.  Urine excretion from the 
urinary bladder contents may occur at a rate of 12 d-1.  In addition to unabsorbed ingesta, 
feces from the GI-tract contain bile from the liver and secretions from the blood (ICRP 
1993).  Fig. 5 shows the compartmental ICRP-67 plutonium systemic model. 
18 
 
 
Fig. 5:  Compartmentalized ICRP Publication 67 plutonium systemic model 
(Adapted from ICRP 1993) 
 
 
LUCIANI AND POLIG PLUTONIUM SYSTEMIC MODEL 
The excretion results using the ICRP-67 plutonium systemic model do not quite 
fit with data from experimental studies and occupational exposures for short time 
periods after exposure (weeks) for injection studies (Luciani and Polig 2000).  The 
ICRP-67 model assumes that radionuclides are also transferred from the ST1 soft tissue 
compartment to the urinary bladder compartment.  The majority of the radionuclide 
excreted through urine is reportedly transferred through this route, but does not make 
sense physiologically (Luciani and Polig 2000).  The Luciani and Polig systemic model 
shows much better agreement with experimental studies and occupational exposures 
19 
 
including the curve constructed by Khokhryakov et al. (Khokhryakov et al. 2004), which 
was based on a large database of excretion data.  The Luciani and Polig plutonium 
systemic model is the same as the ICRP-67 systemic model for plutonium, with some 
exceptions.  The activity that was transferred from the ST1 compartment to the urinary 
bladder compartment now goes to the blood compartment.  Some of the transfer rates 
from compartment to compartment were changed based on studies on blood activity, 
autopsy data, fecal excretion, and urinary excretion optimization (Luciani and Polig 
2000).  Also, the bone system was altered to allow for time-dependent transfer rates, as 
suggested in ICRP Publication 70 (ICRP 1995).  Fig. 6 shows the compartmentalized 
Luciani and Polig plutonium systemic model. 
 
 
Fig. 6: Compartmentalized Luciani and Polig plutonium systemic model 
(Adapted from Luciani and Polig 2000) 
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INTERNAL DOSIMETRY CONSIDERATIONS WITH BIOKINETIC MODELS 
 This section summarizes the dosimetry concepts used in ICRP-30 and ICRP-60.  
The dosimetry models are not shown in all their detail.  Specific dosimetry methods and 
values can be obtained from the actual ICRP-30 and ICRP-60 documents (ICRP 1979, 
and ICRP 1991). 
ICRP-30 DOSIMETRY FOR PLUTONIUM 
The ICRP-30 dosimetry method calculates the total committed dose equivalent to 
assess the dose to an organ or tissue over a period of 50 years after an intake of 
radioactive material.  This is calculated using eqn (3) (ICRP 1979): 
 
(3) 
𝐻50,𝑇(𝑇 ← 𝑆) =  1.6 × 10
−10  𝑈𝑆 [𝑆𝐸𝐸 𝑇 ← 𝑆 ]  
 
where: 
 𝐻50,𝑇(𝑇 ← 𝑆) = the committed dose equivalent to target organ or tissue T from 
each transformation occurring in source organ or tissue S 
 (1.6 × 10−10) = the conversion factor so that the committed dose equivalent can 
be expressed in Sv and the specific effective energy can be expressed in MeV/g 
 𝑈𝑠 = the total number of transformations of a radionuclide occurring in the 
source organ or tissue S over a period of 50 years after intake.  This value is 
calculated using the biokinetic models. 
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 𝑆𝐸𝐸(𝑇 ← 𝑆) = the specific effective energy imparted by the radionuclide that 
transformed in S and gets absorbed in target organ or tissue T 
The total number of transformations occurring in the lung is calculated by the ICRP-30 
respiratory tract model described earlier.  The total number of transformations occurring 
in each organ of the GI-tract is calculated by the ICRP-30 GI-tract model.  After a 
radionuclide passes through the respiratory or GI-tract, it is translocated to the body 
fluids and then to the specific tissues or organs of interest for plutonium.  Clearance rates 
and organs of interest are given in the ICRP-30 metabolic data.  The total calculated 
transformations for an organ is then applied to eqn (3) with the other calculated values to 
assess the committed dose equivalent to the target.  The specific effective energy can be 
calculated from Eq. 4 (ICRP 1979): 
 
(4) 
𝑆𝐸𝐸(𝑇 ← 𝑆)𝑗 =  
𝑌𝑖𝐸𝑖𝐴𝐹(𝑇 ← 𝑆)𝑖𝑄𝑖
𝑀𝑇
𝑖
 
 
where: 
 𝑆𝐸𝐸(𝑇 ← 𝑆)j = the specific effective energy for radionuclide j in MeV/g 
 𝑌𝑖  = the yield of radiations of type i per transformation of radionuclide j 
 𝐸𝑖  = the average energy of radiation i in MeV 
 𝐴𝐹(𝑇 ← 𝑆)i = the absorbed fraction is the fraction of energy absorbed in the 
target organ T per emission of radiation i in source S.  With exception to mineral 
bone and the GI-tract, the absorbed fractions for electrons and alpha particles 
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equals one when the source is the target and zero when the source is not the 
target (ICRP 1979). 
 𝑄𝑖  = the quality factor for radiation of type i 
 𝑀𝑇  = the mass of the target organ in g 
The yield and average energy of radiation used in this report for plutonium decay were 
taken from the nuclear decay data in the MIRD format website (Tuli and Burrows 2007).  
The mass of the source and target organs used for the ICRP-30 plutonium dosimetric 
system in this report were taken from ICRP-30.  The quality factor used for alpha 
particles emitted by plutonium was taken from ICRP-30.  The committed dose 
equivalent for each target organ is then used to calculate the committed effective dose 
equivalent using eqn (5) (ICRP 1979): 
 
(5) 
𝐻𝐸 =  𝑤𝑇𝐻50,𝑇
𝑇
 
where: 
 𝐻𝐸  = the committed effective dose equivalent after the total committed dose 
equivalent for each organ is weighted and summed 
 𝑤𝑇  = the tissue weighting factor for the target organ T.  These values are 
calculated by taking the ratio of the individual risk for the target T to the sum of 
all the risk coefficients. 
The tissue weighting factors used in this report were taken from ICRP-30.  The effective 
dose equivalent can be used to calculate the annual limit on intake (ALI) to make sure 
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that intakes are below the limits for occupational exposure.  ICRP-30 used eqn (6) to 
calculate the maximum annual intake (ICRP 1979). 
 
(6) 
𝐼 × 𝐻𝐸 𝑝𝑒𝑟 𝐵𝑞 𝑖𝑛𝑡𝑎𝑘𝑒 ≤ 0.05 Sv 
𝐼 × 𝐻50,𝑇(𝑝𝑒𝑟 𝐵𝑞 𝑖𝑛𝑡𝑎𝑘𝑒) ≤ 0.5 Sv  
 
where: 
 I (in Bq) is the annual intake of the radionuclide. The ALI is the greatest value of 
I which still satisfies each of the equations in eqn (6). 
 0.05 Sv = the annual limit for stochastic effects 
 0.5 Sv = the annual limit for non-stochastic effects 
ICRP-60 DOSIMETRY FOR PLUTONIUM 
ICRP-60 treats dosimetry very similar to ICRP-30 with few differences.  The 
quality factor of ICRP-30 was replaced by the radiation weighting factor (wR).  ICRP-60 
recommended different values than ICRP-30 for tissue weighting factors (wT).  ICRP-60 
also uses the committed effective dose to assess the tissues weighted dose to the body for 
a period of 50 years after intake.  This is shown in eqn (7) (ICRP 1991).   
 
(7) 
𝐸 𝜏 =  𝑤𝑇 × 𝐻𝑇(𝜏)
𝑇
 
 
where: 
 E(τ) = the committed effective dose 
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 wT = the ICRP-60 tissue weighting factor 
 HT(τ) = the committed equivalent dose integrated over time 
The committed equivalent dose is the sum of the dose to each organ over a 50 year 
period after intake multiplied by the radiation weighting factor.  The committed 
equivalent dose is calculated similar to eqn (3).  The number of transformations 
occurring in organs other than the lung and those from the ICRP-30 GI-tract were 
calculated using systemic models instead of the ICRP-30 plutonium dosimetry model.  
The ICRP-60 dosimetry method also recommended new dose limits for occupational 
workers.  This includes an effective dose limit of 20 mSv per year averaged over five 
years with a further provision that the effective dose should not exceed 50 mSv in any 
single year (ICRP 1991).  There were also non-stochastic limits placed on the lens of the 
eye, the skin, and the hands and feet.  Radiation weighting factors and tissue weighting 
factors from ICRP-60 were used in this report for all combinations except that which 
include the full ICRP-30 plutonium dosimetry model.  Even if the ICRP-30 respiratory 
model and GI-tract model were used in a combination that includes a systemic model 
other than used for plutonium in ICRP-30, the ICRP-60 dose method was still used.   
UNCERTAINTY 
 Uncertainty in dose measurements arises from each element in the dose 
determination process.  This includes uncertainties in measurement, assessment of intake 
from measurement, and assessment of dose from the intake (ICRP 1997).  The 
uncertainty in measurement of activity, through in vivo measurements, excretion data, 
monitoring devices, etc., is the easiest stage to assess uncertainty.  This is provided that 
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the measurements are in sufficient quantity above a decision level to reduce the error 
from counting statistics (ICRP 1997).  Uncertainty in assessing the intake from these 
measurements and the dose from the intake seems to be the most difficult to quantify.  It 
is difficult to assess the uncertainty due to an unknown time of intake and unknown 
individual kinetics.  Reference parameters for each model are given based on probability 
density functions which reflect the confidence to the estimation of the parameter (ICRP 
1991).  ICRP-66 reference parameters have variability and uncertainty with their use.  
Variability is the range of values that can be used for each parameter based on the 
known range of each parameter.  Uncertainty in each parameter refers to the range of 
values a parameter may have due to incomplete knowledge of the true value (Marsh et 
al. 2005).  Since the range of the parameters can give large differences in results, the 
recommended values give conservative dose estimates.  If enough information is 
available for specific individuals, then individual-specific parameters can be used to 
assess dose.  This is especially true for transfer rates or parameters that have a large 
effect on dose estimates.  For example, the F1 value has a large effect on dose estimates 
for ingestion intakes and the absorption parameters, Ss, Sr, and fr, along with AI transport 
are important for inhalation intakes.  Care should be taken to collect all available 
information regarding these values as possible (Luciani et al. 2001).  For cases with 
large amounts of data in which the time of intake is known there is a step-by-step 
procedure to give guidance on the order of which parameter values should be varied 
when analyzing measurements (Marsh et al. 2005). 
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 For the reasons mentioned above, an estimate of the level of uncertainty when 
assessing an intake is difficult to achieve and the reference parameters used should give 
a nominal value of intake (ICRP 1997).  Then each contributing factor to the uncertainty 
may be analyzed according to the situation.
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CHAPTER III 
MATERIALS AND METHODS 
SIMULINK COMPUTER MODELING 
 Simulink is a software package used to model dynamic systems.  Simulink 
provides a graphical user interface that allows differential equations to be modeled as 
block diagrams that are connected as one would draw on paper.  This is a useful tool for 
modeling the transfer of radionuclides throughout the body as a system of coupled 
differential equations.  This code uses subsystems so that the user can view the entire 
model from the top level or double click on a subsystem to see increasingly more detail 
in lower levels.  Computer modeling is necessary for this research as each system 
(respiratory, GI, and systemic) is represented by large numbers of coupled, first-order 
differential equations.  The Simulink program used in this research was included with 
MATLAB and Simulink student version package 7.4.0 R2007a.1  Among the advantages 
of using Simulink to model radionuclide transfer throughout the body compared to 
commercial dose calculating packages are the capability of altering the intakes to allow 
for fluctuating or chronic intakes, and the ability to change transfer parameters for 
specific individual kinetics. 
 Figs. 7-9 show a sample model used for this research.  This is included to show 
the subsystem and block diagram method that Simulink used to solve the coupled, 
differential equations describing radionuclide transfer.  Figs. 7-9 describe the ICRP-30 
GI-tract system.  Fig. 7 shows the complete ICRP-30 GI-tract system from the top level.  
                                                 
1 MATLAB & Simulink Student Version: Getting started with Simulink user manual 
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This includes the inputs for radionuclide inflow from the respiratory tract, the F1 value 
specific for the radionuclide being modeled, the initial activity entering the GI-tract, and 
the radionuclide half life.  This diagram also shows output displays for the activity and 
the number of transformations occurring in each compartment of the GI-tract.  Each of 
the subsystems of the GI-tract (stomach, small intestine, upper large intestine, and lower 
large intestine) is shown in Fig. 8.  This diagram is seen by double clicking on the main, 
GI-track system block shown in Fig. 7.  Fig. 8 shows how the output of one subsystem is 
connected to the input of another subsystem to model the flow of radionuclides from one 
compartment to another.  This couples the differential equations that describe each 
subsystem.  Fig. 9 shows the lowest block diagram level used to solve the differential 
equation of the stomach subsystem.  The block diagram in Fig. 9 is obtained by double 
clicking on the stomach subsystem in the block diagram of Fig. 8.  The block diagram, 
shown in Fig. 9, is used to solve eqn (8): 
          
(8) 
𝑑𝑞𝑖(𝑡)
𝑑𝑡
= 𝐼 (𝑡) +  𝜆𝑗 ,𝑖𝑞𝑗 − (𝜆𝑅 +  𝜆𝑖 ,𝑗 )𝑞𝑖
𝑛
𝑗=1
𝑗≠1
𝑛
𝑗=1
𝑗≠𝑖
 
 
where:  qst(t) is the activity in the stomach at time t, λst is the biological clearance rate 
from the stomach compartment to the small intestine compartment, λr is the radioactive 
decay constant of the radionuclide, and I is the rate of radionuclide transfer from the 
respiratory tract to the GI-tract. 
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Fig. 7: Top level block diagram of the ICRP 30 GI-tract model 
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Fig. 8: Subsystem block diagram showing each compartment of the GI-tract model
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Fig. 9: Lowest level block diagram of the stomach subsystem 
 
 
PROCEDURES 
 To meet the objectives, the ICRP-30 GI-tract model, the ICRP-30 respiratory 
tract model, the ICRP-66 respiratory tract model, the ICRP-67 plutonium systemic 
model, and the Luciani and Polig plutonium systemic model were put into block 
diagrams in similar fashion to Figs. 7-9 using Simulink.  These models were used for 
excretion analysis and dosimetry purposes.  The ICRP-30 plutonium dosimetry model 
was also built for dosimetry comparisons with each combination that used ICRP-60 
dosimetry values.  The above biokinetic models were used to calculate total radionuclide 
transformations in tissues or organs of interest.  Specific configuration parameter 
settings were used with each model and are important to keep constant for each model to 
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allow reproducibility.  A variable-step type solver was used so that the step-size changes 
from step to step, allowing smaller steps when the model state changes rapidly and larger 
steps when the model state changes slowly.  This reduces the simulation time; especially 
when the activity transfer rate levels off over time.  Each model used the ode45 
(Dormand-Prince) solver.  This is the default solver for variable-step models in 
Simulink.  If any of the simulations failed to run, a different solver could be chosen, but 
this did not occur in any of the simulations for this research.  The relative and absolute 
tolerance levels were chosen to be low (10-16) because using the default tolerances gave 
inaccurate results at low values due to a higher acceptable error.  Decreasing the 
tolerance increases the simulation time, but improved the results significantly. 
 After each system was modeled in Simulink, the systems were combined for 
statistical comparisons.  The combinations used to represent the human body in this 
study and compare excretion results were: 
1. Combined ICRP-30 respiratory tract model, ICRP-30 GI-tract model, and ICRP-
67 plutonium systemic model. (Combination 1) 
2. Combined ICRP-66 respiratory tract model, ICRP-30 GI-tract model, and ICRP-
67 plutonium systemic model. (Combination 2) 
3. Combined ICRP-30 respiratory tract model, ICRP-30 GI-tract model, and 
Luciani and Polig plutonium systemic model. (Combination 3) 
4. Combined ICRP-66 respiratory tract model, ICRP-30 GI-tract model, and 
Luciani and Polig plutonium systemic model. (Combination 4) 
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Once these models were built, the 239Pu specific properties were added to each (ICRP 
1997; Tuli and Burrows 2007).  These included a half-life of 24,110 years, an F1 value of 
10-5, an initial activity of zero Bq, and the biological decay constants used for each 
compartment.  The default form of plutonium (oxide form as PuO2) was used in this 
study.  Since the size of particles were unknown, 1 μm AMAD sized particles were used 
with combinations which included the ICRP-30 respiratory tract model and 5 μm 
AMAD sized particles were used with combinations which included the ICRP-66 
respiratory tract model.  Each model was set up so that the daily urinary and fecal 
excretion could be plotted versus time.  Each of the above models’ excretion and dose 
values were checked and matched well with published results (ICRP 1979, ICRP 1994, 
ICRP 1997, Bair 1995, Potter 2002). 
 After the models were built, the daily urinary and fecal excretion amounts were 
plotted versus time, and a comparison was made for each mode of intake (inhalation, 
ingestion, and wound).  This was done to assess the possibility of interchanging models 
when assessing intakes.  Each model used a 1 Bq intake of 239Pu for comparison. 
After the comparison, the models were applied to the case study to assess the 
workers intake.  Not enough biokinetic information or excretion data are available for 
the worker so using individual-specific parameters are not an option to study this intake.  
Reference parameters given for each model were used throughout the investigation.  The 
mode and time of intake was established based upon the excretion and area monitoring 
data.  This was the most difficult and error prone task, as the positive bioassay results 
were unexpected, and neither the mode nor the time of intake was known.  To assess the 
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mode of intake, the fecal excretion measurements from the worker along with the error 
in each measurement were modeled versus time, with the first data point set as day one.  
This was done to compare the worker’s fecal excretion measurements to the excretion 
output for the biokinetic models in Simulink, and to get a general idea of which mode of 
intake gave the correct form of daily excretion rates.  Combination 1 was used to judge 
the assumed mode of radionuclide intake because the ICRP-30 respiratory and GI-tract 
models are currently the recommended models by the U.S. NRC (U.S. NRC 1993).  
These models were combined with the ICRP-67 plutonium systemic model so that the 
excretion data could be modeled.  Even though Combination 1 was used to compare to 
the workers excretion data, it should not matter which combination was used because 
they each show the same general form in excretion results and an exact match is not 
needed for comparison to the workers data.  The model was simulated with different 
modes of intake (ingestion, wound, and inhalation) to get an idea of which could fit the 
workers bioassay data best.  Once the mode of intake was assumed, the time of intake 
had to be decided upon.  This was done based on the time the worker was at the plant 
and the area monitoring data.   
 Once the mode and time of intake were decided upon, each of the combinations 
were used to compare the total intake of plutonium.  Eighteen simulations were run for 
each combination (three for each of the worker’s six positive fecal measurements) so 
that the model excretion results match each of the worker’s excretion measurements and 
upper and lower measurement error values.  For example, Combination 1 was used with 
the assumed mode and time of intake.  One simulation was run with a certain intake, so 
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that the excretion results from the model would match the upper limit of the error bar for 
the first bioassay data point of the worker.  Another simulation was run with an intake 
amount so that model excretion results would match the lower limit of the error bar for 
the first bioassay data point of the worker.  A third simulation was run with an intake 
amount so that model excretion results would match the first bioassay data point of the 
worker.  These same steps were implemented for the next data point for the worker, and 
so on.  These steps allowed the intake to be calculated using a minimized chi-squared fit, 
weighted by the inverse of the variance for each excretion data point.  The equations 
used are shown in eqn (9).  This method was implemented with each of the other 
combinations to compare the intakes that would be calculated (Knoll 2000). 
 
(9) 
 𝑥 =
 𝑎𝑖𝑥𝑖
𝑁
𝑖=1
 𝑎𝑖
𝑁
𝑖=1
 
𝑎𝑗 =
1
𝜎𝑥𝑗
2
  
1
𝜎𝑥𝑖
2
𝑁
𝑖=1
 
−1
 
1
𝜎 𝑥 
2 =  
1
𝜎𝑥𝑖
2
𝑁
𝑖=1
 
 
where:  𝑥  is the best value of the assessed intake, xi is an individual intake to match a 
single worker excretion point, ai is the weighting factor to be given to each individual 
excretion point, N is the number of excretion data points, 𝜎𝑥𝑖 is the error in the intake that 
matches a single excretion points error limit, and 𝜎 𝑥  is the error in the best assessed 
intake value based on propagating the error in each excretion measurement. This 
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assesses the best intake by giving more weight to the excretion measurements with 
smaller error. 
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CHAPTER IV 
RESULTS 
COMPARISON OF EXCRETION RATES 
Each of combinations 1-4 were simulated for acute inhalation, ingestion, and 
wound modes of intakes of 1 Bq of 239Pu to compare the predicted daily fecal and 
urinary excretion values.  Figs. 10-12 show how the predicted daily fecal and urinary 
excretion rates change with time.  Fig. 10 shows the daily excretion rates for an acute 
inhalation mode of intake.  Fig. 10A shows that Combinations 1 and 3 gave similar fecal 
excretion rates and Combinations 2 and 4 gave similar fecal excretion rates.  This is 
because the respiratory models use different retention times and transfer rates to the 
blood or GI-tract.  The fact that Combinations 1 and 3 and Combinations 2 and 4 gave 
similar fecal excretion rates is because the GI-tract is responsible for the majority of the 
fecal excretion up to about 4,000 days for plutonium.  This is due to the small F1 value 
for plutonium, which indicates a small fraction of the radionuclides passing through the 
GI-tract goes to the blood.    Combinations 2 and 4 have no noticeable differences in the 
daily fecal excretion rates for 10,000 days post intake.  Fig. 10B shows that each 
combination gives a different urinary excretion rate as a function of time.  The daily 
urinary excretion rate in Fig. 10B is orders of magnitude lower than the daily fecal 
excretion rate for each combination.  This is why bioassay by fecal analysis is preferred 
over urinary analysis for this class of inhaled radionuclide.  Radionuclides must pass 
through the systemic model before being excreted through urine, while most of the 
excreted activity through feces travels from the respiratory model directly to the GI tract 
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model.  Fig. 10B also shows that the ICRP-30 respiratory tract model transfers more 
activity to the systemic model than the ICRP-66 respiratory tract model by comparing 
Combination 1 to Combination 2 or by comparing Combination 3 to Combination 4.  
Using a combination with the ICRP-30 respiratory system will give a higher urinary 
excretion rate than using a combination with the ICRP-66 respiratory system.  This 
figure also shows that using a combination with the ICRP-67 plutonium systemic model 
will give a higher urinary excretion rate than using a combination with the Luciani and 
Polig plutonium systemic model.  This could be in part to the transfer of activity from 
the ST1 compartment to the urinary bladder contents compartment of the ICRP-67 
model. 
Fig. 11 shows the daily excretion rates for an acute ingestion intake of plutonium.  
Combinations 1 and 2 and Combinations 3 and 4 give the same excretion rates for 
10,000 days after intake.  This is because the respiratory models are not important for a 
pure ingestion intake and the choice of respiratory model is irrelevant.  The daily fecal 
excretion rate, shown in Fig. 11A, is very similar for each combination and implies that 
the fraction of fecal excretion coming from the ICRP-67 and Luciani and Polig systemic 
models are in close agreement for ingestion intakes.  The similarity is also because most 
of the fecal excretion comes from material passing through the GI-tract for plutonium 
and the fecal excretion from material passing through the systemic system has a lesser 
role.  Fig. 11B shows that the daily urinary excretion values are higher when a 
combination uses the ICRP-67 plutonium systemic model as opposed to the Luciani and 
Polig plutonium systemic model (same as with inhalation intake).   
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Fig. 10:  Daily excretion rates versus time for acute inhalation of one Bq of 239Pu. 
 A:  Daily fecal excretion rate  B:  Daily urinary excretion rate 
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Fig. 11:  Daily excretion rates versus time for acute ingestion of 1 Bq of 239Pu  
A:  Daily fecal excretion rate  B:  Daily urinary excretion rate 
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B:
 
Fig. 12:  Daily excretion rates versus time for acute intake from wound of 1 Bq of 239Pu  
A:  Daily fecal excretion rate  B:  Daily urinary excretion rate 
 
Fig. 12 shows the daily excretion rates for an acute intake from a wound or 
injection.  Figs. 12A and 12B show that combinations 1 and 2 have no noticeable 
differences in the daily excretion rates and combinations 3 and 4 have no noticeable 
differences in the daily excretion rates for 10,000 days post intake.  This is as expected 
because only the GI-tract and systemic models are important for this mode of intake.  
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Fig. 12B shows that again the daily urinary excretion values are higher when the 
combination uses the ICRP-67 plutonium systemic model as opposed to the Luciani and 
Polig plutonium systemic model.  Fig. 12 also shows that unlike the inhalation and 
ingestion modes of intake, the excretion rates for feces and urine are of similar orders of 
magnitude when there is an intake from a wound.  This is important because it shows 
that bioassay measurements using urine would be important for this mode of intake. 
CASE STUDY RESULTS 
 Combination 1 was used to decide upon the correct mode of intake for the 
worker.    From the workers fecal bioassay data, it was obvious that an ingestion mode of 
intake could be ruled out because the predicted daily fecal excretion rate drops almost 
ten orders of magnitude after ten days, which did not match the worker’s fecal bioassay 
measurements.  Wound and inhalation intakes have fecal excretion rates that drop two 
and three orders of magnitude, respectively, over a period of about 10 days, but the 
worker’s daily fecal excretion data drops less than an order of magnitude in 10 days.  A 
chronic or fluctuating intake could explain the lower slope in the worker’s excretion 
data, however, it is unlikely to have a chronic intake from a wound over a long period of 
time.  Also, Fig. 12 shows that an intake from a wound would show positive urine 
bioassay results that would give similar excretion rates to that of the fecal bioassay 
results.  There was only one positive urine sample of the worker for 239Pu and this value 
was approximately two orders of magnitude lower than the fecal bioassay results, so it 
can be assumed that the worker did not solely have an intake from a wound.  This leads 
to the assumption of a chronic inhalation mode of intake over a certain time period.  This 
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is consistent with air monitoring data because the daily activity detected was relatively 
unchanging when the worker was in areas containing radioactivity.  There was a spike in 
the worker’s bioassay data about 60 days after the first measurement.  This occurred 
when the worker was placed on restriction outside of radioactive work areas.  This can 
only be explained by a separate intake from the first assumed chronic inhalation intake.  
This is consistent with either an acute inhalation intake, a short chronic inhalation intake, 
or an ingestion intake.  Area monitoring data did show elevated daily activity detected in 
areas where the restricted worker could have been at this time (areas with no radiation 
work).  Other workers also showed similar levels in their bioassay measurements during 
this time frame.  Based on the elevated levels read by the area monitors over a period of 
about five days, a five day chronic inhalation intake is assumed during this time period. 
 The time period of the intake is much harder to estimate if it is unknown, 
especially for chronic intakes.  This is because daily excretion rates from chronic intakes 
tend to level off until the chronic intake ceases.  Many more bioassay data points would 
be needed to get a better idea of the time of intake.  Also, many urine bioassay data 
points could also be beneficial so that the urinary daily excretion could be modeled, but 
the measurements must be very sensitive for this class of radionuclide.  The time of 
intake can be judged based on the worker’s time of employment at the facility and the 
area monitoring data.  Although the area monitors should not be used to assess a 
quantitative intake amount because of the dependence on monitor location, they should 
be used to get a general trend as to the fluctuations in the amount of measured radiation 
over time.  This can give a good indication to the time frame of intake.  The facility had 
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relatively constant monitoring data over time when the worker was in areas containing 
radioactivity, which is consistent with a chronic mode of intake.  It has recently been 
shown that in situations where an intake has occurred in a monitoring interval and there 
is no indication about the actual time of intake, then the only unbiased estimate of intake 
is obtained by assuming a constant chronic intake throughout the monitoring period 
(Birchall et al., 2007).  This leads to the assumption that there was a constant chronic 
intake since the worker started working in the monitored waste area.  It is also assumed 
that the worker did not receive any intake when placed outside of radiological areas for a 
period of two months in the middle of the work period.  
 As stated above, it was assumed that the worker has two separate chronic 
inhalation intakes, one since the worker started in areas containing radioactive materials 
and ending when the worker was placed on work restriction, and the other beginning two 
months after the worker was placed on restriction and lasting for a period of five days.  
This fluctuating intake was input using ‘if’ and ‘else’ blocks.  Each model combination 
was used to assess the intakes to the worker based on the fecal excretion measurements.  
Since there were two separate chronic intakes, the chi-squared method was used with the 
first three bioassay measurements to assess the first chronic intake.  Once the original 
chronic intake was assessed, this value was used in the intake input and the chi-squared 
method could be applied to the final three bioassay measurements to assess the second 
chronic intake.  Fig. 13 shows the calculated intakes based on the chi-squared method 
for each combination.  This shows the calculated initial chronic intake and the second 
calculated chronic intake when the worker was placed on restriction.  Fig. 13 shows that 
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Combinations 1 and 3 give similar intakes as well as Combinations 2 and 4.  This is due 
to the fact that Combinations 1 and 3 use the ICRP-30 respiratory tract model and 
Combinations 2 and 4 use the ICRP-66 respiratory tract model.  Combinations using the 
ICRP-30 respiratory tract model gave a smaller initial chronic inhalation intake, but a 
larger final inhalation chronic intake compared to combinations using the ICRP-66 
respiratory tract model.  The uncertainty shown in Fig. 13 is not the overall uncertainty 
in the intake, but the uncertainty due to the propagation of the error in the measured 
activity from the fecal bioassay data.  It is tough to quantify the total uncertainty of the 
intake in this case where the time and complete mode of intake are unknown.  Fig. 14 
shows the calculated target functions for each assumed intake.  The target function is a 
measure of the deviation of the measured excretion values from the theoretically 
predicted values (Luciani and Polig 2000).  If more excretion data points were given or 
if the kinetic information of the worker were better understood then the target function 
could be used to optimize model parameters.  Fig. 14 shows that the initial assumed 
chronic inhalation intake gives a much higher deviation than the second assumed chronic 
inhalation intake.  Fig. 14 also shows that combinations using either of the systemic 
models gave the same deviation as long as the respiratory tract model was held constant.  
This is not the case for the respiratory model as it seems that combinations involving the 
ICRP-66 respiratory tract model deviate much more with the assumed initial chronic 
inhalation intake.  However, combinations using the ICRP-66 respiratory tract model 
deviate less for the final assumed chronic intake. 
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Fig. 13:  Calculated intake rates (Bq/s) for each combination 
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Fig. 14:  Calculated target functions for each intake 
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of the combinations provided.  Table 1 shows the calculated committed effective dose 
equivalent values using the ICRP-30 plutonium dosimetry model for each of the 
assessed intakes.  The ICRP-30 dosimetry is widely used today due to its simplicity and 
Table 1 shows its comparison with the calculated committed effective doses using the 
assessed intakes from the different combinations. 
 
Table 1:  Doses calculated by each combination for the intake assessed 
  
Committed Effective 
Dose (Sv) 
Committed Effective 
Dose Equivalent (Sv) 
Combination 1 0.00098 0.00140 
Combination 2 0.00018 0.00175 
Combination 3 0.00103 0.00135 
Combination 4 0.00019 0.00177 
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CHAPTER V 
CONCLUSIONS 
MODEL COMPARISONS 
 Based on Fig. 10A, it is apparent that any combination will give a similar form of 
the daily fecal excretion for an acute inhalation intake of plutonium.  However, 
interchanging respiratory models to assess an intake can lead to large differences in 
predicted excretion.  The predicted fecal excretion by interchanging respiratory models 
for an inhalation intake has up to a 110% difference for the first 100 days post intake and 
up to 185% difference after 100 days.  Due to the complexity of the ICRP-66 respiratory 
tract model, it would be much simpler if the ICRP-30 respiratory tract model could be 
used to assess an intake from fecal excretion data.  Fig. 10A shows that using the ICRP-
30 respiratory tract model can be sufficient to assess an intake depending on the time 
post intake.  This respiratory model can be used with either the ICRP-67 or the Luciani 
and Polig plutonium systemic models when assessing an intake from fecal bioassay data 
as there is little change in excretion rates when interchanging systemic models.  The 
systemic models are not as interchangeable when assessing an intake based on urine 
bioassay data, as shown in Fig. 10B.  The predicted urine excretion rate can be over an 
order of magnitude different from another combination when interchanging the 
respiratory models.  The predicted urine bioassay results can have up to 75% difference 
by interchanging the systemic models.  However, fecal bioassay is best to assess an 
intake for this class of radionuclide.  
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Fig. 11A shows the predicted fecal bioassay results for each combination when 
there is an ingestion intake.  Choice of respiratory model is not important for an 
ingestion intake.  The largest difference in predicted fecal excretion results occurs during 
a period from 20-40 days post intake (up to 90% difference).  However, the systemic 
models can be interchangeable at any other times post intake when using fecal analyses.  
Again, care should be taken into consideration when assessing an intake using urine 
bioassay measurements.  Using the Luciani and Polig plutonium systemic model will 
give lower urine excretion rates compared to the ICRP-67 plutonium systemic model at 
almost any time post intake (up to 90% difference).  This is noticeable for the ingestion 
intake shown in Fig. 11B.   
Fig 12 shows predicted daily excretion results from wound or injection intakes.  
Again, the interchangeability between respiratory models is unimportant for this mode of 
intake.  There is up to 50% difference between fecal results within the first 10 days post 
intake and up to 95% difference after 10 days.  It is important to take this into 
consideration when deciding which systemic model to use at specific times post intake.  
For fecal bioassay measurements, a combination using the Luciani and Polig plutonium 
systemic model should be used because it matches better with actual studies during this 
time frame after an intake from a wound (Luciani and Polig 2000).  The predicted daily 
urine excretion from the combinations is similar in form to that of an ingestion intake.  A 
combination should be used with the Luciani and Polig systemic model when assessing 
an intake from urine bioassay data because the ICRP-67 plutonium systemic model tends 
to overestimate the predicted urine excretion rate (Luciani and Polig 2000).   
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CASE STUDY 
 The case study used for this research shows the difficulty in assessing an intake 
when the mode, amount, or time or intake is unknown.  Once an assumed mode and time 
frame of intake were decided upon, each combination was used to assess the intake.  It 
was concluded that the worker had two separate chronic inhalation intakes.  This 
conclusion was based upon the fecal bioassay measurements and the air monitoring data.  
The results of the calculated intakes are shown in Fig. 13.  These results show that for 
these chronic inhalation intakes, the estimated intake will differ by about 3% when 
interchanging the two plutonium systemic models.  However, the predicted intakes differ 
by about 30% when interchanging the ICRP-30 or the ICRP-66 respiratory tract models.  
This is due mainly to the differences in the rate of radionuclide transfer from the 
respiratory tract model to the GI-tract model.  The calculated target functions for each 
intake are shown in Fig. 14.  It was shown that the assumed initial chronic inhalation 
intake deviated the most from the measured excretion values for each combination 
compared to the second chronic inhalation intake.  There are many reasons that could 
explain this deviation: 
 The mode of intake may not be entirely from a chronic inhalation intake.  There 
might also be a small intake from the laceration the worker received that would 
affect the excretion measurements.  It would be hard to assess an intake when 
there are competing modes. 
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 Some of the worker’s excretion measurements may be outliers.  With so few 
excretion measurements, an outlier would greatly affect the calculated target 
function and the assessed intake amount. 
 The exact kinetics of the individual worker may not match well with the standard 
parameters given by the biokinetic models used in the combinations.  This would 
affect the rate of excretion of activity from the body. 
 The assessed initial chronic inhalation intake may be wrong.  However, given the 
small amount of bioassay data, the assessed intake seems most probable. 
The second assumed chronic inhalation intake, after the worker was placed on 
restriction, seems to fit each combination very well.  This can be seen in the calculated 
target functions of  Fig. 14.  It is unclear why the assessed second chronic intake fits the 
worker’s excretion measurements much better.  It could be due to the fact that the time 
period of the second intake was much smaller than the first (a few days as opposed to a 
few years).  The reference parameters used in each biokinetic model were mostly based 
upon acute intakes from studies as opposed to chronic intakes. 
The results of the calculated doses from the assessed intakes are shown in Table 1.  
The table shows that interchanging the systemic models for this assumed chronic intake 
gave a difference of dose of up to 10%.  The differences in doses calculated by 
interchanging the respiratory models are almost an order of magnitude different.  The 
differences in calculated doses are both due to the different intake assessments and 
differences in how each model is used to calculate dose.  The lung dose is calculated 
differently using the ICRP-30 respiratory model and the ICRP-66 respiratory model.  
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Table 1 also shows the calculated committed effective dose equivalent for each assessed 
intake using the plutonium ICRP-30 dosimetric model.  The largest difference in 
calculated dose from the assessed intakes is about 30% using this dosimetry model.  It 
may be much more efficient to assess an intake from bioassay data using one of the 
model combinations in this study followed by the use of the ICRP-30 dosimetric model 
to assess the committed effective dose equivalent.  The ICRP-30 dosimetric model 
cannot be used to assess an intake based on excretion data (since it does not give specific 
excretion pathways), but is a computationally efficient model to assess dose once the 
intake is known. 
FUTURE WORK 
There are many possible ways that the methods used in this research could be 
expanded or improved.  Some examples of possible future work include the following: 
 More case studies - This research covered the comparison and interchangeability 
of models used to assess intakes and dose.  The models were then used to assess 
an unknown intake for a case study.  It would be beneficial to use the same 
methods for other case studies involving different modes of intakes with more 
bioassay measurements.  Studying the interchangeability of these models for only 
one case study cannot provide any conclusive results for other intake modes.  
The interchangeability of different models with ingestion or injection intake 
modes is also of importance.  It would also be meaningful to test these models on 
known intakes (including mode, time frame, and amount of intake) to legitimize 
the results.   
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 Inclusion of more biokinetic models - This research could also be expanded to 
include more biokinetic models.  This can include alternative GI-tract models, 
respiratory tract models, or systemic models.  Also, other radionuclides could be 
included in the study.  The ability for certain models to use alternative 
parameters, like the ICRP-66 respiratory tract model, specific to an individual for 
whom monitoring data are available could be addressed if enough bioassay 
measurements are taken and the exact intake is known.   
 More research involving chronic inhalation intakes - The results presented in this 
research regarding the strong deviation from model predictions for long chronic 
inhalation intakes (as shown by the target function) could be studied more in 
detail.  This type of study would need to include known chronic inhalation case 
studies and acute inhalation case studies.  Comparisons could be made about the 
deviations from model predictions.  It may turn out that these biokinetic models 
do not fit well with chronic inhalation intakes over long periods of time. 
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APPENDIX 
ICRP-30 RESPIRATORY TRACT MODEL 
 
 
Upper level of ICRP-30 respiratory tract model 
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Middle level of ICRP-30 respiratory tract model 
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Lower level of ICRP-30 respiratory tract model
61 
 
ICRP-30 GI-TRACT MODEL 
 
 
Upper level of the ICRP-30 GI-tract mode
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Middle level of the ICRP-30 GI-tract model
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Lower level of the ICRP-30 GI-tract model 
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ICRP-67 PLUTONIUM SYSTEMIC MODEL 
 
 
 
 
Upper level of the ICRP-67 plutonium systemic mod
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Lower level for the ICRP-67 plutonium systemic model 
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ICRP-66 RESPIRATORY TRACT MODEL 
 
 
Upper level for the ICRP-66 respiratory tract model 
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Middle level of ICRP-66 respiratory tract model showing rapid and slow dissolution 
sections
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Lower level of the ICRP-66 respiratory tract model 
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LUCIANI AND POLIG PLUTONIUM SYSTEMIC MODEL 
 
 
 
 
Upper level of the Luciani and Polig plutonium systemic mode
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Lower level of the Luciani and Polig plutonium systemic model
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ICRP-30 DOSIMETRY MODEL 
 
75 
 
 
 
 
Lower level of the ICRP-30 dosimetry transfer compartment 
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Middle level of some of the main organs of interest in the ICRP-30 dosimetry model
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